Valuation in Europe – European companies will be less valuable

trend interview

by trend
Valuation in Europe – European companies will be less valuable. An interview with Prof. Aswath Damodaran and Prof. Christopher Kummer about valuation and Mergers & Acquisitions by Trend (Austria)! They also discuss how European companies can make use of M&A to grow their value. […] Read more

Deal Capsule: Transactions In Chemicals & Pharmaceuticals July 2016

Table 1-2 Pharmaceuticals July 2016

by KPMG
The number of completed deals remained high in both sectors in HY1 2016. While total deal value for pharmaceuticals decreased, chemicals witnessed a 40% increase in HY1 2016 versus HY1 2015. Pharmaceutical M&A was impacted by stock market volatility, while new US regulatory rules struck down the $160 billion Pfizer-Allergan merger. Oncology and dermatology were key areas of interest for big pharma, who were especially keen on acquiring biotech assets. […] Read more

Automotive M&A Deals Insights – First Half Of 2016

Automotive M&A Deals Insights – First Half Of 2016

by PricewaterhouseCoopers
Automotive M&A deal value for the first half of 2016 (H1 2016) was down 37%, significantly off the pace experienced in 2015. However, with 257 deals, volume was only down 7%. Despite the overall decline in deal value for the first half of 2016, the overall strength of the automotive industry remains strong as global vehicle assembly is expected to grow at a CAGR of 3.3% through 2022. […] Read more

Power Transactions And Trends, Q2 2016

Power Transactions And Trends, Q2 2016

by Ernst & Young
This Q2 2016 edition of Power transactions and trends reviews quarterly deal activity within the power and utilities (P&U) sector and forecasts the trends that will shape future mergers and acquisitions (M&A). When we consider Q2’s most prominent M&A trends, it’s clear that buyers are still seeking “safe bets” amid ongoing sector and global volatility. […] Read more

Plotting A New Course: The Impact Of Brexit On M&A Activity

Figure 1 UK M&A volumes and values (H1 2005 - H1 2016)

by Deloitte
In the aftermath of the EU referendum vote, the reaction from currency and stock markets has been swift. It is clear that Brexit has shaken investor confidence. However, M&A markets are typically driven by longer term decision making processes. Brexit has created uncertainties and some M&A plans are being put on hold. But we think the post-Brexit tumult creates opportunities as well. In the coming months we expect there will be both threats to M&A dealmakers and unique opportunities for them. […] Read more

Biotechnology Report 2016: Beyond Borders – Returning To Earth

Figure 1 US and European biotechnology centers at a glance 2015

by Ernst & Young
In 2016, the biopharma world is on somewhat unfamiliar footing. After five years of market cap gains and increasingly buoyant capital markets, biotech’s fortunes peaked in 2015. The biotech industry’s cumulative market cap has dropped precipitously over the past nine months. As this year’s Beyond borders report describes, although new records were set in cumulative revenue, net income and R&D spend, growth rates in all three categories have slowed. […] Read more

Deal Capsule: Transactions In Chemicals & Pharmaceuticals April 2016

Deal Capsule: Transactions In Chemicals & Pharmaceuticals April 2016

by KPMG
While the number of completed pharma deals were slightly higher in Q1 2016 versus Q1 2015, deal value was far lower in the absence of any >$10 billion completions. Only one deal exceeded $5 billion in Q1 2016 (versus 8 in Q1 2015). Specialization continues to be a driving force in Q1 2016, especially in sectors such as OTC, rare diseases and oncology. Declines in transaction values were also witnessed in chemicals. Downstream specialty chemicals was the leading focus area, notably in applications, resins and agrochemicals. […] Read more

Pfizer, Allergan deal dead, what could be next?

Pfizer Allergan Merger

by CNBC
A $160 billion merger between Pfizer and Allergan lay in tatters Wednesday and left experts contemplating whether more deals could be hit by new tax rules issued by the U.S. Treasury. The deal, which would have allowed New York-based Pfizer to cut its tax bill by redomiciling to Ireland, has now been formally ended. Fresh rules issued Monday make it tougher for target companies to pass on their overseas registered address and in turn, beneficial tax rates. […] Read more

Metro will sich aufspalten

Metro Diagramm 1

by Handelsblatt
Kurz nach seinem Amtsantritt als Metro-Chef im Januar 2012 setzte Olaf Koch ein Zeichen. Er verlegte sein Büro vom Hauptgebäude der Düsseldorfer Zentrale, der Brücke 1, zur Brücke 13, von wo das Tagesgeschäft der Großhandelsmärkte geführt wird. Damit rückte er „Cash & Carry“ wieder in den Fokus des Handelskonzerns – die Sparte, mit der bei Metro vor gut 50 Jahren alles begann. […] Read more

Are you sure you
want to log out?

Request a Brochure

Request a Brochure

Contact us to discuss your goals and needs!

Contact us to discuss your goals and needs!

Book a Demo

Book a Demo

Contact us to discuss your goals and needs!

Contact us to discuss your goals and needs!